Millions of patients with neurodegenerative disorders may receive therapeutic benefit from gene therapy through a variety of ways, including direct repair of pathogenic mechanisms, neuroprotection, neurorestoration, and symptom control. Therefore, understanding the illness pathophysiology and the necessary temporal and geographic specificity of gene expression are essential for effective therapeutic outcomes. The most thorough transduction of the target structure while preventing leaking into surrounding areas or perivascular spaces is another significant difficulty. In the newest technological era of gene therapy, interventional MRI-guided convection-enhanced delivery (iMRI-CED) is the gold standard for real-time verification of precise vector administration. The availability of this cutting-edge method of neurosurgery should hasten the development of potential preclinical treatments for neurodegenerative illnesses like Parkinson's, Huntington's, and Alzheimer's.
Share this article